Aβ-related biomarkers, such as low Aβ42 in the cerebrospinal fluid (CSF) and positive amyloid-PET scans, precede other AD-related changes (increased CSF tau, decreased cerebral glucose metabolism, brain atrophy, clinical dementia) by years [13]. This evidence concerns the gene MAPT and Alzheimer disease.